The Addictive Diagnostic Value of Apparent Diffusion Coefficients to bpMRI in the Diagnosis of Prostate Cancer

The study is conducted with suspected prostate cancer. Patients with PI-RADS scores of 3-5 after completing prostate bpMRI chose to undergo prostate biopsy. Before patients undergo prostate biopsy, researchers will collecte information on age, BMI, tPSA, f/PSA, PV, PSAD, ADCmean, ADCmin, ADCmax, ADCnormal, maximum lesion diameter, location of major lesions, and so on. For prostate biopsy, systematic prostate biopsy ± bpMRI cognitive fusion targeted prostate biopsy will be completed under the conditions permitted by physical condition, and Gleason score will be clearly given by pathologists if the final diagnosis is prostate cancer. In this study, the pathological result is regarded as the gold standard. ROC curve, area under curve, sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, negative likelihood ratio and other indicators of diagnostic test were calculated. Relevant conclusions are finally drawn by comparing the diagnostic capacity of different ADC values for prostate cancer. Meanwhile, binary logistic regression analysis will also conduct the Odds ratios (ORs) and 95% confidence intervals (CIs) will be recorded.

Inclusion criteria

• The patient met at least one indication of prostate biopsy (Chinese expert consensus on prostate biopsy (2022 edition) https://rs.yiigle.com/cmaid/1442948 );
• Serum PSA test was completed in the patient with tPSA < 100 ng/ml;
• Primary prostate tumor lesion, no history of other tumors;
• Completed 3.0T bpMRI examination, PI-RADS score ≥3 score, the image is clear and readable;
• Patients fully understand the relevant contents of the study and voluntarily sign the informed consent.

Exclusion criteria

• The patient has contraindications for MRI;
• PI-RADS 1-2 of bpMRI;
• The patient had contraindications to prostate biopsy or explicitly refused biopsy;
• bpMRI indicated that the patient had multiple lymph nodes or bone metastases;
• Previous prostate-related surgery;
• The patient refused to sign the informed consent.